Document is current
Any future updates will be listed below
-
Authors
Blauvelt, Andrew https://orcid.org/0000-0002-2633-985X
Kallender, Howard https://orcid.org/0000-0001-5634-883X
Sturm, Daniel https://orcid.org/0009-0001-4413-8429
Li, Qian
Ren, Haobo https://orcid.org/0000-0002-4694-2795
Eichenfield, Lawrence F. https://orcid.org/0000-0002-2760-0474
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03745638 at ClinicalTrials.govnct03745651 at ClinicalTrials.govDocuments that mention this clinical trial
Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies
https://doi.org/10.1007/s13555-024-01219-8
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
https://doi.org/10.1007/s13555-024-01272-3
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
Documents that mention this clinical trial
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
https://doi.org/10.1007/s13555-024-01272-3
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
https://doi.org/10.1007/s40257-021-00610-x
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
https://doi.org/10.1007/s40257-022-00734-8
-
Funding
Funding for this research was provided by:
Incyte
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 2 September 2024
First Online: 7 October 2024
Declarations
:
: Andrew Blauvelt (currently Blauvelt Consulting) has served as a speaker (received honoraria) for AbbVie, Eli Lilly and Company, Pfizer, and UCB; served as a scientific advisor (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, AnaptysBio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, LEO, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx. Howard Kallender, Daniel Sturm, Qian Li, and Haobo Ren are employees and shareholders of Incyte Corporation. Lawrence F. Eichenfield has served as an investigator, consultant, speaker, or data safety monitoring board member for AbbVie, Amgen, Arcutis, Aslan, Castle Biosciences, Dermavant, Eli Lilly, Forte Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, and Sanofi Genzyme.
: Studies were conducted in accordance with Good Clinical Practice guidelines and provisions of the Declaration of Helsinki. All patients provided written informed consent before enrollment. The protocols were approved by the relevant institutional review board or ethics committee at each study center.
